METHODS A prospective, randomized single center study including consecutive patients in stable clinical condition and with lesions amenable to be treated with the BVS stent according to predefined criteria. Patients were randomized to either treatment with BVS or SynergyÔ. The procedure was performed according to operators discretion. Full details of the procedure were collected including use of resources, devices, radiation, contrast and myocardial enzymes and creatinine before and after procedure.
RESULTS A total of 100 patients (124 lesions) were included with no significant differences in baseline characteristics and only a trend to have more lesions treated in the SynergyÔ group. Pre-dilatation was more frequent with BVS (97% vs. 24%;p<0.001). Implanted stents had similar diameter (3AE0.4 mm in BVS and 3AE0.5 mm in SynergyÔ) and length (19AE6 mm in BVS and 20AE8 mm in SynergyÔ) . Post-dilatation was more frequently done with BVS (58% vs. 42%:p¼0.1) using very similar balloons (3.3 mm diameter in both groups) and peak pressure (16 atm and 15 atm respectively). The number of wires and catheters was equivalent. The BVS group showed an increase in use of contrast volume of 10%, increase in radiation of 28% and an increase in the 24 h post-PCI TnI value a 53% higher in comparison with the SynergyÔ group. No cases of contrast-induced nephropathy were noted.
CONCLUSIONS The use of current generation of BVS in comparison with the SynergyÔ stent in a similar lesional setting is associated with a higher use of resources in the procedure, more radiation and a to higher TnI release after PCI. BACKGROUND In the ASSURE registry, the treatment of de-novo coronary artery lesions in a real world setting with everolimus-eluting bioresorbable scaffolds (Absorb, Abbott Vascular, Santa Clara, CA, USA) was associated with favorable clinical 1-year outcomes. The current investigation aimed to assess efficacy and safety over a longer period of time. Here we report on clinical outcomes and angiographic findings at 2 years.
METHODS In the prospective, multicenter registry, 183 consecutive patients received bioresorbable scaffolds at 6 German sites. Two-year outcomes of equal weight were angina status and freedom from major adverse cardiovascular events (MACE) and target vessel failure or revascularization. Quantitative angiography was conducted at followup and in the event of ischemia driven revascularization.
RESULTS
Two-year clinical follow-up was completed in 170 (92.9%) patients. Three (1.8%) patients died for cardiovascular reasons, one from gastrointestinal bleeding, one from sudden cardiac death, and one from cardiorespiratory insufficiency. Five (2.9%) myocardial infarctions due to non-target lesions occurred, and 9 (5.3%) ischemia driven target lesion revascularizations had become necessary because of in-scaffold restenosis. One of the participating centers with a 82.1% (46/56 patients) angiographic follow-up reported on a 20.4% (10/49) rate of ! 70% diameter restenosis through 2 years, half of which associated with symptoms of ischemia. No scaffold thrombosis was observed. Freedom from MACE was 91.6% AE 2.1% (95% CI [87.4% -95,8%]). Ten patients (5.9%) experienced a target vessel failure or revascularization. Clinical improvement was sustained over two years, with no substantial change in the rate of angina pectoris since the 6-and 12-month follow up (16.8% versus 16.9% and 17.3%, respectively). Quantitative angiographic core lab results from 71 patients (38.8%) will be available by August 2015.
CONCLUSIONS Two-year ASSURE results suggest that bioresorbable scaffolds for de-novo coronary artery lesions in daily clinical practice are safe and effective in the mid term. METHODS In the first-in-man ABSORB Cohort B trial, 28 patients with 29 lesions underwent truly serial OCT examinations at 4 different time points (Cohort B1: post-procedure, 6 months, 24 months, and 60 months [n¼13]; B2: post-procedure, 12 months, 36 months, and 60 months [n¼15]) after implantation of an 3.0-mm x 18-mm Absorb scaffold. A frame-by-frame (200 mm) OCT analysis was performed at the 5-mm proximal edge, 5-mm distal edge, and 2-mm in-scaffold margin, whereas the middle 14-mm in-scaffold segment was analyzed at 1-mm intervals.
There was no significant change in the lumen area at the distal edge segment through the entire follow-up period, although at the distal edge segment the lumen area tended to increase between post-procedure and 6 months (Cohort B1: 4.94 AE 1.23 mm 2 for post-procedure; 5.39 AE 1.83 mm 2 for 6 months [p¼0.0520, for post-procedure vs. 6 months]; 4.95 AE 1.26 mm 2 for 24 months; 5.61 AE 2.08 mm 2 for 60 months). In contrast, there was a significant reduction of the lumen in the 2-mm distal margin of the scaffold between post-procedure and 12 months (at the 1-mm margin: 7.31 AE 1.02 mm 2 vs. 5.66 AE 1.26 mm 2 , and 2-mm margin: 7.36 AE 1.04 mm 2 vs. 5.64 AE 1.30 mm 2 , respectively, p¼0.001). There was no significant change of the lumen in the 2-mm distal margin of the scaffold between 12 months and 60 months (at the 1-mm margin: 5.66 AE 1.26 mm 2 vs. 4.89 AE 2.02 mm 2 [p¼0.116], and 2-mm margin: 5.64 AE 1.30 mm 2 vs. 5.18 AE 1.96 mm 2 [p¼0.211]). At the proximal edge segment the lumen area decreased significantly between post-procedure and 12 months (Cohort B2: 7.20 AE 1.75 mm 2 vs. 6.70 AE 1.53 mm 2 p¼0.0168), however between 12 months and 60 months the lumen remained stable (6.70 AE 1.53 mm 2 vs. 6.22 AE 1.83 mm 2 p¼0.4623). The 2-mm proximal margin of scaffold segment also showed a similar change; a significant reduction of lumen area at the first 1-mm edge between post-procedure and 12 months (7.49 AE 1.45 mm 2 vs. 6.55 AE 1.08mm 2 , p¼0.019), however there was no significant change of lumen area at the first 1-mm edge between 12 months and 60 months (6.55 AE 1.08 mm 2 vs. 5.81 AE 1.22 mm 2 , p¼0.508). In the Cohort with 6 months, 24 months, and 60 months follow-up, no significant change was observed in the lumen of the proximal edge segment (6.37 AE 3.18 mm 2 for post-procedure, 6.63 AE 2.68 mm 2 for 6 months, 6.73 AE 2.70 mm 2 for 24 months, 6.69 AE 2.61 mm 2 for 60 months).
CONCLUSIONS In the limited number of serial observations by OCT, some degree of lumen reduction was observed in the proximal edge in the first year after implantation of an Absorb scaffold. However, after one year the lumen at the both proximal and distal edges remained stable. The edge effect seems to be a temporary phenomenon, observed only in the first year after implantation. 
